 Seth Furgeson
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ureteral Obstruction | 3 | 2021 | 62 | 1.390 |
Why?
| | Kidney | 5 | 2023 | 1383 | 1.160 |
Why?
| | Renal Insufficiency, Chronic | 4 | 2024 | 567 | 1.090 |
Why?
| | Group IV Phospholipases A2 | 2 | 2017 | 47 | 1.080 |
Why?
| | Myocytes, Smooth Muscle | 6 | 2018 | 259 | 0.970 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2019 | 444 | 0.940 |
Why?
| | PTEN Phosphohydrolase | 7 | 2019 | 159 | 0.910 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 38 | 0.800 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 17 | 0.760 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 23 | 0.750 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.750 |
Why?
| | Fibrosis | 7 | 2021 | 526 | 0.680 |
Why?
| | Inflammation Mediators | 2 | 2021 | 505 | 0.670 |
Why?
| | Kidney Tubules | 2 | 2019 | 114 | 0.640 |
Why?
| | Cell Dedifferentiation | 2 | 2016 | 30 | 0.600 |
Why?
| | Metabolome | 1 | 2021 | 339 | 0.590 |
Why?
| | Connective Tissue Growth Factor | 1 | 2017 | 24 | 0.570 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2017 | 17 | 0.560 |
Why?
| | Kidney Diseases | 2 | 2017 | 382 | 0.540 |
Why?
| | Nephrosclerosis | 1 | 2016 | 6 | 0.530 |
Why?
| | Renal Dialysis | 2 | 2013 | 423 | 0.520 |
Why?
| | Bone Marrow | 1 | 2017 | 272 | 0.510 |
Why?
| | Optical Imaging | 1 | 2016 | 56 | 0.500 |
Why?
| | Energy Metabolism | 1 | 2021 | 875 | 0.500 |
Why?
| | Angiotensin II | 2 | 2019 | 95 | 0.480 |
Why?
| | Cytokines | 2 | 2021 | 2022 | 0.470 |
Why?
| | Kidney Failure, Chronic | 2 | 2013 | 546 | 0.460 |
Why?
| | Microscopy, Fluorescence | 1 | 2016 | 399 | 0.460 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 39 | 0.450 |
Why?
| | Uremia | 1 | 2013 | 14 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1242 | 0.410 |
Why?
| | Acidosis | 1 | 2013 | 89 | 0.380 |
Why?
| | Inflammation | 2 | 2014 | 2748 | 0.360 |
Why?
| | Epithelial Cells | 2 | 2018 | 1063 | 0.360 |
Why?
| | Pseudohypoaldosteronism | 1 | 2010 | 2 | 0.350 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 68 | 0.340 |
Why?
| | Tunica Intima | 2 | 2010 | 84 | 0.340 |
Why?
| | Carotid Artery Injuries | 1 | 2010 | 41 | 0.330 |
Why?
| | Gene Expression | 1 | 2014 | 1465 | 0.310 |
Why?
| | Peritonitis | 1 | 2009 | 81 | 0.300 |
Why?
| | Cell Proliferation | 4 | 2016 | 2378 | 0.300 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 175 | 0.290 |
Why?
| | Mice, Knockout | 5 | 2021 | 2888 | 0.290 |
Why?
| | Peritoneal Dialysis | 1 | 2009 | 95 | 0.280 |
Why?
| | Disease Models, Animal | 7 | 2024 | 4076 | 0.280 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2023 | 254 | 0.270 |
Why?
| | Vascular Remodeling | 2 | 2019 | 192 | 0.270 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5468 | 0.250 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2008 | 321 | 0.240 |
Why?
| | Animals | 15 | 2024 | 35404 | 0.240 |
Why?
| | Mice | 11 | 2023 | 16982 | 0.240 |
Why?
| | Phenotype | 4 | 2021 | 3062 | 0.230 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 122 | 0.210 |
Why?
| | Chlorthalidone | 1 | 2022 | 7 | 0.200 |
Why?
| | Signal Transduction | 6 | 2019 | 4935 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2014 | 434 | 0.180 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.180 |
Why?
| | Leukocytes | 1 | 2021 | 306 | 0.170 |
Why?
| | Nephrology | 1 | 2020 | 60 | 0.160 |
Why?
| | Cells, Cultured | 5 | 2019 | 4102 | 0.160 |
Why?
| | Chemokine CXCL12 | 2 | 2011 | 79 | 0.160 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 13 | 0.160 |
Why?
| | Rats | 5 | 2019 | 5485 | 0.160 |
Why?
| | Anti-Bacterial Agents | 1 | 2009 | 1708 | 0.160 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2019 | 42 | 0.150 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 485 | 0.150 |
Why?
| | Lymphangiogenesis | 1 | 2017 | 26 | 0.140 |
Why?
| | Sepsis | 1 | 2024 | 576 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 161 | 0.140 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2010 | 443 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2019 | 240 | 0.130 |
Why?
| | Arachidonic Acid | 1 | 2016 | 115 | 0.130 |
Why?
| | Cognition | 1 | 2024 | 1124 | 0.130 |
Why?
| | Actins | 2 | 2018 | 410 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 789 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2018 | 239 | 0.130 |
Why?
| | Dinoprostone | 1 | 2016 | 187 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 373 | 0.120 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2008 | 0.120 |
Why?
| | Gene Silencing | 1 | 2016 | 190 | 0.120 |
Why?
| | Cadherins | 1 | 2016 | 190 | 0.120 |
Why?
| | Humans | 14 | 2024 | 129687 | 0.110 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 30 | 0.110 |
Why?
| | Cell Line | 2 | 2018 | 2779 | 0.110 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 117 | 0.110 |
Why?
| | Macrophages | 1 | 2021 | 1489 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2018 | 402 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2014 | 128 | 0.110 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 277 | 0.100 |
Why?
| | PPAR gamma | 1 | 2014 | 183 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 213 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 855 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 314 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1213 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 537 | 0.090 |
Why?
| | Serum Response Factor | 1 | 2011 | 32 | 0.090 |
Why?
| | Neointima | 1 | 2011 | 15 | 0.090 |
Why?
| | WNK Lysine-Deficient Protein Kinase 1 | 1 | 2010 | 1 | 0.090 |
Why?
| | RNA Interference | 2 | 2010 | 450 | 0.090 |
Why?
| | Male | 8 | 2021 | 63691 | 0.090 |
Why?
| | Epithelial Sodium Channels | 1 | 2010 | 19 | 0.090 |
Why?
| | Internship and Residency | 1 | 2020 | 1052 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2010 | 362 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2010 | 46 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2545 | 0.080 |
Why?
| | Potassium Channels | 1 | 2010 | 149 | 0.080 |
Why?
| | Virginiamycin | 1 | 2009 | 3 | 0.080 |
Why?
| | Linezolid | 1 | 2009 | 20 | 0.080 |
Why?
| | Daptomycin | 1 | 2009 | 19 | 0.080 |
Why?
| | Oxazolidinones | 1 | 2009 | 15 | 0.080 |
Why?
| | Acetamides | 1 | 2009 | 36 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2403 | 0.080 |
Why?
| | Autocrine Communication | 1 | 2008 | 42 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 398 | 0.070 |
Why?
| | Sympathetic Nervous System | 1 | 2008 | 174 | 0.070 |
Why?
| | Immunotherapy | 2 | 2018 | 596 | 0.060 |
Why?
| | Hypoxia | 1 | 2013 | 1085 | 0.060 |
Why?
| | NF-kappa B | 1 | 2010 | 666 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 436 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 680 | 0.060 |
Why?
| | Mutation | 2 | 2018 | 3705 | 0.060 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 391 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2013 | 1894 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2135 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 578 | 0.050 |
Why?
| | Cell Movement | 1 | 2008 | 950 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| | Hyperplasia | 2 | 2018 | 175 | 0.050 |
Why?
| | Mycobacterium bovis | 1 | 2003 | 16 | 0.050 |
Why?
| | BCG Vaccine | 1 | 2003 | 24 | 0.050 |
Why?
| | Mycobacterium Infections | 1 | 2003 | 62 | 0.050 |
Why?
| | Cell Differentiation | 3 | 2018 | 1900 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 198 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1201 | 0.040 |
Why?
| | Prognosis | 1 | 2008 | 3772 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1016 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 347 | 0.040 |
Why?
| | Disease Progression | 2 | 2018 | 2628 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 206 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 79 | 0.040 |
Why?
| | Focus Groups | 1 | 2020 | 450 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 276 | 0.030 |
Why?
| | Blotting, Western | 1 | 2019 | 1204 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 181 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1160 | 0.030 |
Why?
| | Female | 3 | 2018 | 68751 | 0.030 |
Why?
| | RNA | 1 | 2019 | 876 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 902 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 177 | 0.020 |
Why?
| | Adult | 3 | 2023 | 35607 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2011 | 302 | 0.020 |
Why?
| | Models, Animal | 1 | 2011 | 376 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 382 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2008 | 83 | 0.020 |
Why?
| | United States | 1 | 2024 | 13906 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 274 | 0.020 |
Why?
| | Arteries | 1 | 2008 | 265 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 590 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2739 | 0.010 |
Why?
| | Up-Regulation | 1 | 2008 | 836 | 0.010 |
Why?
| | Heart Failure | 1 | 2018 | 2147 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1716 | 0.010 |
Why?
| | Aged | 2 | 2018 | 22101 | 0.010 |
Why?
| | Hepatitis | 1 | 2003 | 47 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2003 | 59 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 31165 | 0.010 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2003 | 226 | 0.010 |
Why?
| | Pneumonia | 1 | 2003 | 619 | 0.010 |
Why?
|
|
Furgeson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|